Basic Genomics

Basic Genomics

Stockholm, Sweden· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.3M

Overview

Basic Genomics is a Stockholm-based private company developing a proprietary synthetic long-read RNA sequencing platform called RNA BaseCode™. The technology bridges the gap between the practicality of short-read sequencing and the detailed, full-transcript information of long-read sequencing by using unique molecular barcodes to assemble short reads into accurate synthetic long reads. This enables researchers to comprehensively analyze RNA isoforms from low-input samples, which is critical for understanding gene function in health and disease. The company appears to be in an early commercial stage, offering both kits and services directly to the research market.

Genetics & Genomics

Technology Platform

RNA BaseCode™: A proprietary synthetic long-read RNA sequencing technology that uses unique molecular barcodes during reverse transcription to assemble standard short-read data into accurate, full-length transcript sequences (isoforms).

Funding History

2
Total raised:$2.3M
Grant$500K
Seed$1.8M

Opportunities

The growing emphasis on RNA biology and alternative splicing in disease research creates a large, expanding market for isoform-resolution tools.
The platform's compatibility with low-input and degraded samples opens opportunities in clinical sample analysis and biomarker discovery.
Strategic partnerships with large pharma or diagnostic companies could accelerate adoption and validate the technology.

Risk Factors

Intense competition from established sequencing giants (Illumina, PacBio, Oxford Nanopore) who are also improving isoform analysis capabilities.
Technological disruption risk if a newer, cheaper, or more accurate method emerges.
Challenges in scaling commercial operations and achieving widespread market penetration as a smaller, private company.

Competitive Landscape

Basic Genomics competes in the niche between high-throughput short-read sequencing (dominated by Illumina) and native long-read sequencing (dominated by PacBio and Oxford Nanopore). It differentiates on accuracy, cost-effectiveness for long-read data, and workflow simplicity. Key competitors include other synthetic long-read methods (e.g., 10x Genomics Linked Reads, Loop Genomics) and bioinformatics tools for isoform reconstruction from short reads.